SFYS2: Sing For Your Saunter Part 2 R33

Sponsor
Washington University School of Medicine (Other)
Overall Status
Recruiting
CT.gov ID
NCT06115382
Collaborator
National Institutes of Health (NIH) (NIH)
74
2
2
25.9
37
1.4

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to compare to rhythm-based walking interventions to enhance gait in people with Parkinson's disease. The main questions it aims to answer are:

  • How does rhythm-based training influence walking performance?

  • How does brain activity change following rhythm-based training? Participants will perform walking to music and walking while singing, and will train on the use of these rhythms for 12 weeks. The investigators will compare the effects of training with music to training with singing.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Self Cueing Training
  • Behavioral: External Cueing Training
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
74 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Sing for Your Saunter: Using Self-Generated Rhythmic Cues to Enhance Gait in Parkinson's
Actual Study Start Date :
Oct 5, 2023
Anticipated Primary Completion Date :
Sep 30, 2025
Anticipated Study Completion Date :
Nov 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Self cueing

Self-cueing training using singing, one hour sessions twice weekly for 12 weeks.

Behavioral: Self Cueing Training
Group classes led by a music therapist and using singing as a self-generated cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.

Experimental: External cueing

External cueing using music, one hour sessions twice weekly for 12 weeks.

Behavioral: External Cueing Training
Group classes led by a music therapist and using music as an external cue, with a focus on rhythm perception, rhythm generation and synchronization of movement to rhythms.

Outcome Measures

Primary Outcome Measures

  1. Gait speed [Baseline and 12 weeks]

    How quickly someone walks

  2. MRI Bold Beta Weights [Baseline and 12 weeks]

    Measure of blood oxygen levels in different brain regions indicative of level of activity within different brain regions

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. at least 30 years of age

  2. diagnosis of idiopathic, typical Parkinson disease according to the UK Brain Bank Criteria

  3. Hoehn & Yahr stages 2-3 (mild to moderate disease severity)

  4. evidence of walking impairment (score at least 1 on gait item of MDS_UPDRS)

  1. stable on all PD medications for at least 2 months prior to study entry 5) willing and able to provide informed consent 6) right-handed
Exclusion Criteria:
  1. diagnosis of any other neurological condition

  2. a score of 2 or greater on item # 3 on the freezing of gait questionnaire

  3. significant cognitive impairment

  4. unstable medical or concomitant illnesses or psychiatric conditions which, in the opinion of the investigators, would preclude successful participation

  5. cardiac problems that interfere with ability to safely participate

  6. orthopedic problems in the lower extremities or spine that may limit walking

  7. contraindications for magnetic resonance imaging

  8. unable to walk for 10 continuous minutes independently

  9. left-handed

  10. uncontrolled tremor or dyskinesia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington University School of Medicine Saint Louis Missouri United States 63108
2 Washington University School of Medicine Saint Louis Missouri United States 63108

Sponsors and Collaborators

  • Washington University School of Medicine
  • National Institutes of Health (NIH)

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gammon M Earhart, Professor, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT06115382
Other Study ID Numbers:
  • 202309088
First Posted:
Nov 3, 2023
Last Update Posted:
Nov 3, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 3, 2023